Modeling of pharmacodynamic (PD) biomarkers (BM) related to CDK4/6 inhibition and exploratory BM-response (progression free survival [PFS]) analyses in patients with advanced breast cancer. This is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback